Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis

“Multiple myeloma is moving very fast right now. There are a lot of new agents…that are exciting, including oral options,” said Tomer Mark an associate professor of medicine, clinical director of the Plasma Cell Disorders Program, and clinical director of the Autologous Stem Cell Transplant Program, in the Department of Medicine-Hematology, at the University of Colorado School of Medicine.